Most and least shorted mid- to mega-cap healthcare stocks at the end of July
Seeking Alpha News (Mon, 3-Aug 9:35 AM ET)
Bausch + Lomb Earnings Call Signals Growing Momentum
TipRanks (Fri, 31-Jul 8:22 PM ET)
RBC Capital Keeps Their Buy Rating on Bausch + Lomb Corporation (BLCO)
TipRanks (Fri, 31-Jul 10:55 AM ET)
TipRanks (Thu, 30-Jul 1:00 PM ET)
Bausch Health posts a record rally after Q2 beat, guidance hike
Seeking Alpha News (Thu, 30-Jul 11:18 AM ET)
Evercore ISI Remains a Hold on Bausch + Lomb Corporation (BLCO)
TipRanks (Thu, 30-Jul 9:07 AM ET)
Wells Fargo Sticks to Their Hold Rating for Bausch + Lomb Corporation (BLCO)
TipRanks (Thu, 30-Jul 7:16 AM ET)
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
Business Wire (Wed, 29-Jul 6:58 AM ET)
Bausch + Lomb Launches EyeGility Inserter Preloaded IOL Delivery System in the United States
Business Wire (Thu, 16-Jul 7:00 AM ET)
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
Business Wire (Thu, 9-Jul 4:30 PM ET)
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Bausch & Lomb trades on the NYSE stock market under the symbol BLCO.
As of August 4, 2026, BLCO stock price declined to $16.68 with 289,967 million shares trading.
BLCO has a beta of 0.92, meaning it tends to be less sensitive to market movements. BLCO has a correlation of 0.17 to the broad based SPY ETF.
BLCO has a market cap of $5.96 billion. This is considered a Mid Cap stock.
Last quarter Bausch & Lomb reported $1 billion in Revenue and $.16 earnings per share. This beat revenue expectation by $26 million and met earnings estimates .
In the last 3 years, BLCO traded as high as $21.69 and as low as $10.45.
The top ETF exchange traded funds that BLCO belongs to (by Net Assets): MGMT, DFAX, DFIC, GUSA, SHRT.
BLCO has underperformed the market in the last year with a return of +23.6%, while the SPY ETF gained +25.3%. In the last 3 month period, BLCO fell short of the market, returning +2.3%, while SPY returned +7.3%. However, in the most recent 2 weeks BLCO has outperformed the stock market by returning +4.4%, while SPY returned +3.9%.
BLCO support price is $16.41 and resistance is $17.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLCO shares will trade within this expected range on the day.